With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170911-92-9,tert-Butyl 4-(4-aminophenyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.
To a stirred solution of tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate (27-1)( 400.0 mg, 1.44 mmol) in DMF (1.0 mL) were added 3-bromopiperidine-2,6-dione (1-2) (552 mg,5 2.88 mmol) and DIPEA (795 J.L, 4.31 mmol) and the reaction mixture was stirred at roomtemperature for 16 hours. It was diluted with saturated aqueous NaHC03 solution and extractedwith 20% IP A/DCM. Organic layer was dried over sodium sulfate and concentrated. Crudematerial was purified by column chromatography using (0%-2% MeOH/DCM) to afford tert-butyl4-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperazine-1-carboxylate (27-3) (300 mg, 772J.mol,10 53.6 %) as offwhite solid. LC/MS (ES+): m/z 389 [M+H]+, 170911-92-9
As the paragraph descriping shows that 170911-92-9 is playing an increasingly important role.
Reference£º
Patent; C4 THERAPEUTICS, INC.; PHILLIPS, Andrew, J.; NASVESCHUK, Christoper, G.; HENDERSON, James, A.; LIANG, Yanke; HE, Minsheng; DUPLESSIS, Martin; CHEN, Chi-Li; (791 pag.)WO2018/237026; (2018); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics